A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
• • A total body weight of more than (\>) 50 kg
• • Nonsmoker or ex-smoker for at least 3 months before the first study drug dose
• Key Exclusion Criteria:
• • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
• • Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
• • Other protocol defined Inclusion/Exclusion criteria may apply.